Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Pediatric aHUS
NCT01193348Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2010
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Proportion of Patients With Complete TMA Response at 55 weeks. Started Sep 2010; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT01193348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193348.